← Leaderboards
Daniel Savic
St. Jude Children'S Research Hospital
$2,767,925
Attributed
$3,175,109
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $814.4K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,175,109 · 2
By mechanism
R01$3,175,109 · 2
Top collaborators
- Yong Cheng1 shared
Most similar at St. Jude Children'S Research Hospital
Same institution · by research overlap
- Mary V. Relling$28,942,987
- William E. Evans$20,051,064
- Jun J. Yang$13,116,250
- Charles G. Mullighan$25,123,215
- Hongbo Chi$35,087,263
Others in their field
Other Emerging Leaders on “Resistance”
- John Damon Chodera · Sloan-Kettering Inst Can Research$56,843,703
- Urs Ochsner · Crestone, Inc.$40,390,611
- Ryan Cirz · Revagenix, Inc.$40,209,479
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Michael Dignam · National Institute Of Allergy And Infectious Diseases$30,845,607
- Daniel Pevear · Venatorx Pharmaceuticals, Inc.$24,789,028
Research focus
ResistancePrecision MedicineGenomeReporterVariantChromatinGenesGenetic VariationPhenotypeRegulatory ElementResponseUntranslated RnaDrug ResistanceDna SequenceCell LineCohortClustered Regularly Interspaced Short Palindromic RepeatsGenetic VariantMapsPharmaceutical PreparationsCausal VariantCatalogsAllelesChromosome Mapping
Grant awards (6)
Deciphering the underlying structure of the glucocorticoid gene regulatory network$814,368
R01 · FY2025 · HG · contact PI
Characterizing noncoding GWAS variants in acute lymphoblastic leukemia treatment outcome$488,482
R01 · FY2023 · CA · contact PI
Characterizing noncoding GWAS variants in acute lymphoblastic leukemia treatment outcome$481,751
R01 · FY2022 · CA · contact PI
Characterizing noncoding GWAS variants in acute lymphoblastic leukemia treatment outcome$486,113
R01 · FY2021 · CA · contact PI
Characterizing noncoding GWAS variants in acute lymphoblastic leukemia treatment outcome$444,543
R01 · FY2020 · CA · contact PI
Characterizing noncoding GWAS variants in acute lymphoblastic leukemia treatment outcome$459,852
R01 · FY2019 · CA · contact PI